Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

Thomas R.Jeffry Evans; Masatoshi Kudo; Richard S. Finn; Kwang Hyub Han; Ann Lii Cheng; Masafumi Ikeda; Silvija Kraljevic; Min Ren; Corina E. Dutcus; Fabio Piscaglia; Max W. Sung

doi:10.1038/s41416-019-0534-2

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

Thomas R.Jeffry Evans, Masatoshi Kudo, Richard S. Finn, Kwang Hyub Han, Ann Lii Cheng, Masafumi Ikeda, Silvija Kraljevic, Min Ren, Corina E. Dutcus, Fabio Piscaglia, Max W. Sung

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

2 Citations (Scopus)

Abstract

This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Original language	English
Pages (from-to)	625
Number of pages	1
Journal	British journal of cancer
Volume	121
Issue number	7
DOIs	https://doi.org/10.1038/s41416-019-0534-2
Publication status	Published - 2019 Oct 1

Bibliographical note

Publisher Copyright:
© 2019, The Author(s).

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41416-019-0534-2

Fingerprint

Dive into the research topics of 'Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)'. Together they form a unique fingerprint.

Cite this

Evans, T. R. J., Kudo, M., Finn, R. S., Han, K. H., Cheng, A. L., Ikeda, M., Kraljevic, S., Ren, M., Dutcus, C. E., Piscaglia, F., & Sung, M. W. (2019). Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). British journal of cancer, 121(7), 625. https://doi.org/10.1038/s41416-019-0534-2

Evans, Thomas R.Jeffry ; Kudo, Masatoshi ; Finn, Richard S. et al. / Correction : Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). In: British journal of cancer. 2019 ; Vol. 121, No. 7. pp. 625.

@article{74530fa95a464f53b972a0fe237a75df,

title = "Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)",

abstract = "This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.",

author = "Evans, {Thomas R.Jeffry} and Masatoshi Kudo and Finn, {Richard S.} and Han, {Kwang Hyub} and Cheng, {Ann Lii} and Masafumi Ikeda and Silvija Kraljevic and Min Ren and Dutcus, {Corina E.} and Fabio Piscaglia and Sung, {Max W.}",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = oct,

day = "1",

doi = "10.1038/s41416-019-0534-2",

language = "English",

volume = "121",

pages = "625",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "7",

}

Evans, TRJ, Kudo, M, Finn, RS, Han, KH, Cheng, AL, Ikeda, M, Kraljevic, S, Ren, M, Dutcus, CE, Piscaglia, F & Sung, MW 2019, 'Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)', British journal of cancer, vol. 121, no. 7, pp. 625. https://doi.org/10.1038/s41416-019-0534-2

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). / Evans, Thomas R.Jeffry; Kudo, Masatoshi; Finn, Richard S. et al.
In: British journal of cancer, Vol. 121, No. 7, 01.10.2019, p. 625.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction

T2 - Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

AU - Evans, Thomas R.Jeffry

AU - Kudo, Masatoshi

AU - Finn, Richard S.

AU - Han, Kwang Hyub

AU - Cheng, Ann Lii

AU - Ikeda, Masafumi

AU - Kraljevic, Silvija

AU - Ren, Min

AU - Dutcus, Corina E.

AU - Piscaglia, Fabio

AU - Sung, Max W.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

AB - This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

UR - http://www.scopus.com/inward/record.url?scp=85069924178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069924178&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0534-2

DO - 10.1038/s41416-019-0534-2

M3 - Comment/debate

C2 - 31363170

AN - SCOPUS:85069924178

SN - 0007-0920

VL - 121

SP - 625

JO - British journal of cancer

JF - British journal of cancer

IS - 7

ER -

Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M et al. Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6). British journal of cancer. 2019 Oct 1;121(7):625. doi: 10.1038/s41416-019-0534-2

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6)

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this